Abstract | BACKGROUND: PATIENTS AND METHODS: We prospectively evaluated the efficacy and aqueous penetration of intravenous IFO, oral TRO and their active 4-hydroxy (4-OH) metabolites in 10 patients with IOL. Doses varied from 1500 to 2000 mg/m2/day on days 1-3 for IFO and from 150 to 400 mg/day (continuous or intermittent administration) for TRO. Four patients had newly diagnosed disease, and six had relapsed after pretreatment. RESULTS: All patients responded to first treatment with IFO or TRO, and both of two patients responded to re-treatment with IFO on ocular relapse. Progression-free survival from the first treatment with IFO or TRO was > or = 6-18 months. In six of six patients, 4-OH metabolites were detected in the aqueous humor at a concentration of 0.32-1.56 microM immediately after IFO infusion with an aqueous/serum ratio of 0.19-0.54. 4-OH metabolites could be detected in one of three patients at a concentration of 7.2 microM 3-16 h after ingestion of TRO. CONCLUSIONS: IFO and TRO are active in IOL. IOL patients evidence aqueous penetration of 4-OH metabolites after intravenous administration of IFO.
|
Authors | K Jahnke, T Wagner, N E Bechrakis, G Willerding, S E Coupland, L Fischer, E Thiel, A Korfel |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 16
Issue 12
Pg. 1974-8
(Dec 2005)
ISSN: 0923-7534 [Print] England |
PMID | 16219622
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Cyclophosphamide
- trofosfamide
- Ifosfamide
|
Topics |
- Aged
- Antineoplastic Agents, Alkylating
(pharmacokinetics)
- Cyclophosphamide
(analogs & derivatives, pharmacokinetics)
- Disease-Free Survival
- Eye Neoplasms
(drug therapy, metabolism, pathology)
- Humans
- Ifosfamide
(pharmacokinetics)
- Infusions, Intravenous
- Lymphoma, B-Cell
(drug therapy, metabolism, pathology)
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, metabolism, pathology)
- Middle Aged
- Prospective Studies
- Salvage Therapy
|